Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Biotechnology Licensing: How Has the Balance of Power Shifted?

Published by: Decision Resources

Published: Oct. 21, 2005 - 19 Pages

The price of this publication has been reduced due to age. The full price was $1,900.

Table of Contents


Overview

Biotechnology Licensing Trends

Industry Perspectives

Licensing Best Practice: Case Studies

Outlook




Table 1. Comparison of Sales and R&D Expenditure Pre- and Postmerger, 1999-2004

Table 2. Impact of Mergers on Pipeline Size and Composition

Table 3. Mid-2005 Status of Agents That Were in the Pipelines of Constituent Companies at the Time of Merger

Table 4. Therapeutic Sector Participation by Company, Mid 2005

Table 5. Leading Target Indications: Point of Merger and Current Pipeline Comparison




Figure 1. Impact of Mergers on Development Status Pipeline Composition

Figure 2. Postmerger Evolution of the Therapeutic Focus of the Mega Corporations

Figure 3. Postmerger Evolution of AstraZeneca’s Pipeline

Figure 4. Postmerger Evolution of GlaxoSmithKline’s Pipeline

Figure 5. Postmerger Evolution of Pfizer’s Pipeline

Figure 6. Postmerger Evolution of Sanofi-Aventis’s Pipeline

Figure 7. Externally Sourced Product Opportunities: Point of Merger and Current Pipeline Comparison

Abstract

An analysis of the pipelines of four "mega corporations" that emerged during the first half of the decade-AstraZeneca, GlaxoSmithKline, Pfizer, and Sanofi-Aventis-shows that although spending on R&D increased significantly between 1999 and 2004, the number of new chemical entities in late-stage research has declined for all four mega corporations. How successful has the pipeline enhancement process been in practice? This report examines the pipelines of the four mega corporations to see what lessons can be learned. We seek to determine the impact that the megamergers have had on pipelines-whether mergers have resulted in a greater “breadth” of activity across therapy areas and increased productivity or whether the amalgamation of pipelines has had a deleterious effect on R&D output. The question is vital for these corporations because their profitability over the coming decades will depend, to a considerable extent, on the ability of their R&D operations to bring new drugs to market.

Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


advertise with us

 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2008